BACKGROUND: Macrophage inhibitory cytokine-1 (MIC-1) is part of the TGF-beta superfamily. Raised concentrations of MIC-1 in serum arise in several disease states, can be detected in normal individuals, and can partly be genetically determined. We aimed to investigate whether MIC-1 has a role in atherothrombosis. METHODS: We did a prospective, nested, case-control study in 27628 initially healthy women. Of these women, we established baseline concentrations of MIC-1 in 257 who subsequently had myocardial infarction, stroke, or died from a cardiovascular event (cases) and in 257 matched for age and smoking status, who did not report cardiovascular disease during 4-year follow-up (controls). We also assessed polymorphisms in the MIC-1 gene (MIC-1 H and MIC-1 D) in all 514 women. FINDINGS: MIC-1 concentrations were higher at baseline in women who subsequently had cardiovascular events than in those who did not (618 vs 538 pg/mL, p=0.0002). Concentrations above the 90th percentile (>856 pg/mL) were associated with a 2.7-fold increase in risk (95% CI 1.6-4.9, p=0.001). This effect was independent of traditional cardiovascular risk factors and at least additive to that of C-reactive protein. There was no significant association between MIC-1 polymorphism and vascular events. INTERPRETATION: MIC-1 could be a novel target for cardiovascular disease prevention.
BACKGROUND:Macrophage inhibitory cytokine-1 (MIC-1) is part of the TGF-beta superfamily. Raised concentrations of MIC-1 in serum arise in several disease states, can be detected in normal individuals, and can partly be genetically determined. We aimed to investigate whether MIC-1 has a role in atherothrombosis. METHODS: We did a prospective, nested, case-control study in 27628 initially healthy women. Of these women, we established baseline concentrations of MIC-1 in 257 who subsequently had myocardial infarction, stroke, or died from a cardiovascular event (cases) and in 257 matched for age and smoking status, who did not report cardiovascular disease during 4-year follow-up (controls). We also assessed polymorphisms in the MIC-1 gene (MIC-1 H and MIC-1 D) in all 514 women. FINDINGS:MIC-1 concentrations were higher at baseline in women who subsequently had cardiovascular events than in those who did not (618 vs 538 pg/mL, p=0.0002). Concentrations above the 90th percentile (>856 pg/mL) were associated with a 2.7-fold increase in risk (95% CI 1.6-4.9, p=0.001). This effect was independent of traditional cardiovascular risk factors and at least additive to that of C-reactive protein. There was no significant association between MIC-1 polymorphism and vascular events. INTERPRETATION:MIC-1 could be a novel target for cardiovascular disease prevention.
Authors: Anand Rohatgi; Parag Patel; Sandeep R Das; Colby R Ayers; Amit Khera; Abelardo Martinez-Rumayor; Jarett D Berry; Darren K McGuire; James A de Lemos Journal: Clin Chem Date: 2011-11-07 Impact factor: 8.327
Authors: Raaj S Mehta; Mingyang Song; Navya Bezawada; Kana Wu; Xabier Garcia-Albeniz; Teppei Morikawa; Charles S Fuchs; Shuji Ogino; Edward L Giovannucci; Andrew T Chan Journal: J Natl Cancer Inst Date: 2014-02-24 Impact factor: 13.506
Authors: Vivek Narayan; Elizabeth W Thompson; Biniyam Demissei; Jennifer E Ho; James L Januzzi; Bonnie Ky Journal: J Am Coll Cardiol Date: 2020-06-02 Impact factor: 24.094
Authors: Thomas J Wang; Kai C Wollert; Martin G Larson; Erin Coglianese; Elizabeth L McCabe; Susan Cheng; Jennifer E Ho; Michael G Fradley; Anahita Ghorbani; Vanessa Xanthakis; Tibor Kempf; Emelia J Benjamin; Daniel Levy; Ramachandran S Vasan; James L Januzzi Journal: Circulation Date: 2012-08-20 Impact factor: 29.690